Kamada (NASDAQ:KMDA) Downgraded to “Sell” at ValuEngine

ValuEngine lowered shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, ValuEngine reports.

A number of other equities analysts also recently commented on the stock. BidaskClub downgraded shares of Kamada from a buy rating to a hold rating in a research note on Tuesday, June 30th. HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Kamada in a research note on Tuesday, May 19th. TheStreet upgraded shares of Kamada from a c+ rating to a b- rating in a research note on Wednesday, May 20th. Finally, Zacks Investment Research downgraded shares of Kamada from a buy rating to a hold rating in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. Kamada has a consensus rating of Hold and an average target price of $10.00.

Shares of KMDA stock opened at $8.83 on Thursday. The company has a market capitalization of $393.11 million, a P/E ratio of 16.35 and a beta of 1.20. The company’s 50-day simple moving average is $8.12 and its two-hundred day simple moving average is $6.86. Kamada has a one year low of $4.40 and a one year high of $9.91.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Phoenix Holdings Ltd. lifted its position in Kamada by 2.8% during the first quarter. Phoenix Holdings Ltd. now owns 1,033,092 shares of the biotechnology company’s stock valued at $5,884,000 after acquiring an additional 28,524 shares during the last quarter. Renaissance Technologies LLC lifted its position in Kamada by 13.0% during the fourth quarter. Renaissance Technologies LLC now owns 937,829 shares of the biotechnology company’s stock valued at $6,405,000 after acquiring an additional 107,605 shares during the last quarter. Meitav Dash Investments Ltd. lifted its position in Kamada by 20.3% during the first quarter. Meitav Dash Investments Ltd. now owns 889,050 shares of the biotechnology company’s stock valued at $5,213,000 after acquiring an additional 149,762 shares during the last quarter. Norges Bank purchased a new stake in Kamada during the fourth quarter valued at approximately $2,740,000. Finally, Marshall Wace LLP lifted its position in Kamada by 188.8% during the fourth quarter. Marshall Wace LLP now owns 82,446 shares of the biotechnology company’s stock valued at $565,000 after acquiring an additional 53,903 shares during the last quarter. Hedge funds and other institutional investors own 12.91% of the company’s stock.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

See Also: Sell-Side Analysts

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.